AbbVie’s HCV treatment receives first for shorter treatment cycle

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Jakkapan Sapmuangphan)
(Image: Getty/Jakkapan Sapmuangphan)

Related tags: AbbVie, Gilead, Mavyret, Hcv

US FDA granted expanded approval for Mavyret that will allow patients to be treated for the hepatitis C virus in eight weeks.

AbbVie’s Mavyret (glecaprevir/pibrentasvir) can now be administered to treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients, across all genotypes, in eight weeks.

It becomes the first once-daily treatment to have this duration, after previous standard treatments had needed 12 weeks or more.

AbbVie’s immediate rivals in the space, Gilead, possess treatment with such schedules, including Epclusa (sofosbuvir/velpatasvir) and Harvoni (ledipasvir/sofosbuvir) – though Gilead launched ‘early’ generic versions​ of these treatments to compete on pricing.

According to clinical trials undertaken by AbbVie, Mavyret was able to manage a sustained virologic response 12 weeks after treatment in 98% of patients, when they were treated with an eight-week dosing schedule.

“With more than 2.3 million people in the US still living with chronic HCV, access to shorter-term, eight-week treatment options can help us move closer to achieving the WHO’s goal of eliminating HCV by 2030,”​ said Robert Brown, professor of medicine at Weill Cornell Medical College, on the approval.

In AbbVie’s second-quarter financials​, the company posted that Mavyret had brought in $784m (€718m) in net revenue globally for the company.

AbbVie managed these sales despite an arrangement being made with the WHO for the distribution of Mavyret in low- and middle-income countries at a discount​.

Related news

Show more

Related products

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us


View more